Despite Wide-Ranging Cost Cutting Measures, Ciphergen s Q4 Net Loss Widens to $9.2 Million | GenomeWeb

Ciphergen reported during its fourth-quarter earnings call last week that it is continuing to cut costs by reducing headcount, trimming R&D spending, paring back shipping costs, diminishing travel expenses, and subletting space.

Despite these cutbacks, Ciphergen's fourth-quarter revenues fell 35 percent to $6.6 million from $10.1 million during the year-ago period, resulting in a net loss of $9.2 million, or $0.26 per share, versus a net income of $10.3 million, or $0.35 per share in the fourth quarter of 2004.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.